Feb. 26 at 1:00 AM
Have gained familiarity with several genetic testing and diagnostics companies on a personal level this past year. My husband has had 6 cancers, two of which are extremely rare. This has led to the identification of an inherited genetic condition called Muir Torre Syndrome, so he is under constant surveillance for tumor markers. We've come to know
$ONC for treatment of Lymphoma,
$TEM for optimal therapy selection, and
$NTRA to monitor the presence/return of Merkel Cell and colon cancer. Each of these companies does important work, and I hope they all have the financial traction to thrive. 🙏
$ONC is up 13% YTD and 36% in the past year. They report earnings tomorrow.
$TEM dropped significantly post-earnings today amid market concerns about growth sustainability.
$NTRA shares popped following positive results from the Phase 2 SINERGY trial for head and neck cancer, which showed strong response rates using the Signatera MRD-guided treatment.
